BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:15 PM
 | 
Jul 07, 2009
 |  BC Extra  |  Top Story

Denosumab tops Zometa in Amgen Phase III

Amgen Inc. (NASDAQ:AMGN) said denosumab was superior to Zometa zoledronic acid on the primary endpoint of time to the first on-study skeletal related event (SRE) in a Phase III trial to prevent SREs associated with breast cancer. To...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >